Advaxis licenses novel tumour-associated antigen for cancer
This article was originally published in Scrip
Executive Summary
Advaxis, a company based in Princeton, New Jersey which is developing immunotherapies for cancer and infectious diseases, has exclusively licensed the use of tumour-associated antigen ISG15 in its Lm-LLO based immunotherapies from the University of Pennsylvania. Recently published data demonstrate that Advaxis’ Lm-LLO immunotherapy reduced primary and metastatic breast tumours in an animal model when directed against the novel protein ISG15, the company said.